...
首页> 外文期刊>Cancer biology & therapy >Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer
【24h】

Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer

机译:使用贝伐单抗和他莫昔芬维持疗法治疗转移性乳腺癌的五年稳定疾病

获取原文
获取原文并翻译 | 示例
           

摘要

Bevacizumab and Tamoxifen are valid therapeutic options for metastatic breast cancer (mBC) patients. In this report, we describe a 47 year old woman with mBC successfully treated with a maintenance therapy with Bevacizumab+Tamoxifen. A maintenance approach using 2 different drugs with different targets and mechanism of action, such as anti-angiogenic and anti-hormonal treatment is particularly intriguing because they affect different pathways involved in mBC progression. Further studies including a large number of patients are needed, in order to select women who could benefit from this maintenance approach.
机译:贝伐单抗和他莫昔芬是转移性乳腺癌(mBC)患者的有效治疗选择。在本报告中,我们描述了一名47岁的mBC妇女,成功接受贝伐单抗+他莫昔芬的维持治疗。使用两种具有不同靶标和作用机制的不同药物(例如抗血管生成和抗激素治疗)的维持方法特别吸引人,因为它们会影响参与mBC进程的不同途径。为了选择可以从这种维持方法中受益的女性,需要包括大量患者在内的进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号